TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06603844: First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Sponsor: Corbus Pharmaceuticals Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06603844 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06603844 Rescue Dossier →